Skip to main content
Terug
SGIPF logo

Sugi Holdings Co.,Ltd.

Datakwaliteit: 100%
Overbought
SGIPF
OTC Healthcare Medical - Pharmaceuticals
€ 16,29
€ 0,00 (0,00%)
Marktkapitalisatie: 2,95B
Dagbereik
€ 16,29 € 16,29
52-Weeksbereik
€ 16,29 € 16,29
Volume
100
50D / 200D Gem.
€ 16,29 / € 16,29
Vorige Slotkoers
€ 16,29

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 0,4
P/B 0,0 2,9
ROE % 10,6 3,8
Net Margin % 2,9 3,9
Rev Growth 5Y % 252,9 10,0
D/E 0,2 0,2

Belangrijkste Punten

Revenue grew 252,94% annually over 5 years — strong growth
Earnings grew 16,88% over the past year
ROE of 10,61% — decent returns on equity
Debt/Equity of 0,18 — conservative balance sheet
Generating 10,91B in free cash flow
P/E of 0,11 — trading at a low valuation

Groei

Revenue Growth (5Y)
252,94%
Revenue (1Y)17,94%
Earnings (1Y)16,88%
FCF Growth (3Y)841,45%

Kwaliteit

Return on Equity
10,61%
ROIC10,78%
Net Margin2,93%
Op. Margin4,85%

Veiligheid

Debt / Equity
0,18
Current Ratio1,14
Interest Coverage187,50

Waardering

P/E Ratio
0,11
P/B Ratio0,01
EV/EBITDA-0,11
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 17,94% Revenue Growth (3Y) 1238,72%
Earnings Growth (1Y) 16,88% Earnings Growth (3Y) 1257,15%
Revenue Growth (5Y) 252,94% Earnings Growth (5Y) 237,40%
Profitability
Revenue (TTM) 878,02B Net Income (TTM) 25,69B
ROE 10,61% ROA 5,19%
Gross Margin 31,33% Operating Margin 4,85%
Net Margin 2,93% Free Cash Flow (TTM) 10,91B
ROIC 10,78% FCF Growth (3Y) 841,45%
Safety
Debt / Equity 0,18 Current Ratio 1,14
Interest Coverage 187,50 Dividend Yield 0,01%
Valuation
P/E Ratio 0,11 P/B Ratio 0,01
P/S Ratio 0,00 PEG Ratio 1,02
EV/EBITDA -0,11 Dividend Yield 0,01%
Market Cap 2,95B Enterprise Value -4,49B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 878,02B 744,48B 4,90B 5,44B 5,66B
Net Income 25,69B 21,98B 139,47M 168,61M 198,24M
EPS (Diluted) 141,96 121,46 0,77 0,91 1,07
Gross Profit 275,04B 228,84B 1,49B 1,67B 1,70B
Operating Income 42,56B 36,62B 232,31M 279,46M 319,51M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 495,12B 390,56B 2,59B 2,93B 3,27B
Total Liabilities 244,41B 157,20B 1,00B 1,07B 1,38B
Shareholders' Equity 250,70B 233,36B 1,59B 1,86B 1,88B
Total Debt 45,35B 837,00M 14,34M 20,05M 21,88M
Cash & Equivalents 52,79B 43,43B 254,06M 294,19M 524,17M
Current Assets 246,48B 199,05B 1,47B 1,67B 2,01B
Current Liabilities 216,08B 136,65B 858,66M 891,91M 1,21B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#180 of 820
58
Growth Price/Sales Ratio Focus (Ken Fisher)
#240 of 616
42
Value Defensive Investing (Benjamin Graham)
#393 of 708
25

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026